

11/28/00
U.S. PTO

12-04-00

Box SEOr

DIVISION - CONTINUATION - CONTINUATION-IN-PART
APPLICATION TRANSMITTAL FORM

Attorney Docket No.: A-579C

	Anticipated Classification Of This Application:		Prior Application:	
	Class	Subclass	Examiner	Art Unit

To the Assistant Commissioner for Patents:

This is a request for filing a continuation divisional continuation-in-part application, under 37 CFR 1.53(b), of pending prior international application Serial No. PCT/US00/01871 filed on January 27, 2000, of Yoshinaga et al.

for NOVEL POLYPEPTIDES INVOLVED IN IMMUNE RESPONSE

For CONTINUATION or DIVISIONAL APPLNs only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 1b, below, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

1. Transmitted herewith are:
 - 115 pages of specification, 7 pages of claim(s) and 1 page of abstract, totaling 123 pages.
 - 35 sheet(s) of drawings.
 - 4 pages of Unsigned Oath or Declaration by the applicant(s):
 - a. Newly executed (original or copy)
 - b. Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional appns. only)
 - 28 pages of Sequence Listing; computer readable format of sequence listing; sequence statement.
2. The filing fee is calculated below:

For	Number Filed	Number Extra	Rate	Fee
Total Claims	94	- 20 =	74	x \$18.00 = \$1,332.00
Independent Claims	9	- 3 =	6	x \$80.00 = 480.00
Multiple Dependent Claims	1			+ \$270.00 = 270.00
Basic Fee				\$710.00 = 710.00
				Total Filing Fee \$2,792.00

3. Please charge Deposit Account No. 01-0519, in the name of Amgen Inc., in the amount of \$2,792.00. An original and one copy are enclosed.
4. Throughout the prosecution of this application, if any extension of time is necessary, please consider this a request therefor.
5. The Commissioner is hereby authorized to charge any additional filing fees which may be required by the accompanying application, any additional fees which may be required during pendency of this application as required by 37 CFR 1.16 or 1.17, or credit any overpayment to Deposit Account No. 01-0519 throughout the prosecution of this application.
6. Cancel in this application original claims _____ of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)

EXPRESS MAIL CERTIFICATE

Express Mail mail labeling number: EL360691010US

Date of Deposit: November 28, 2000

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Box Patent Application, Assistant Commissioner for Patents, Washington, DC 20231.

Lynne Buchsbaum

Printed Name

Signature

11/28/00
U.S. PTO
09/728420

7. Preliminarily, please amend the specification by inserting before the first line the following:

--This application is a continuation-in-part division of international application Serial No. PCT/US00/01871, filed January 27, 2000, which is a continuation-in-part of application Serial No. 09/264,527, filed March 8, 1999, which is a continuation of application Serial No. 09/244,448, filed February 3, 1999, which are hereby incorporated by reference.--

8. Transfer the drawings from the prior application to this application and abandon said prior application as of the filing date accorded this application. A duplicate copy of this sheet is enclosed for filing in the prior application file. (May only be used if signed by person authorized by § 1.138 and before payment of base issue fee.)

8a. New formal drawings are enclosed.

9. Priority of application Serial No. PCT/US00/01871 filed on January 27, 2000 in PCT (country) is claimed under 35 USC 119.

9a. The certified copy has been filed in prior application Serial No. _____ filed _____

10. The prior application is assigned of record to Amgen Inc.

11. A preliminary amendment is enclosed.

12. Also enclosed _____

13. Other: _____

14. The power of attorney in the prior application is to:
Ron K. Levy, Registration No. 31,539; Steven M. Odre, Registration No. 29,094; and
Robert B. Winter, Registration No. 34,458

a. The power appears in the original papers in the prior application.

b. Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.

c. Address all future communications to
Robert B. Winter
at the address below.

Signator: Assignee of complete interest

Attorney or agent of record



Robert B. Winter
Attorney/Agent for Applicant(s)
Registration No. 34,458
Phone: (805) 447-2425
Date: November 28, 2000

Please send all future correspondence to:

U. S. Patent Operations/RBW
Dept. 4300, M/S 27-4-A
AMGEN, INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799